STRONTIUM RANELATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS: IMPACT OF VITAMIN D RECEPTOR AND MONOCYTE CHEMOATTRACTANT PROTEIN-1 GENE POLYMORPHISMS ON BONE MINERAL DENSITY: A PILOT STUDY

Objective: to investigate the impact of VDR and MCP-1 gene polymorphisms on the efficiency of 12-month therapy with strontium ranelate (SR) in women with postmenopausal osteoporosis (OP).

Subjects and methods. The investigation enrolled 34 postmenopausal women (mean age 65±8 years), who was diagnosed with OP by lumbar spine and/or proximal femur examinations using a Hologic QDR 4500W X-ray bone densitometer. The gene polymorphisms of VDR (BsmI) and MCP-1 (-2518A/G) were genotyped by polymerase chain reaction, followed by restriction fragment length polymorphism analysis.

Results and discussion. The carriers of the BB and Вb genotypes of the VDR gene had a statistically significantly lower increase in the bone mineral density (BMD) of the lumbar spine than those of the homozygous recessive bb genotype (p = 0.024 and p = 0.022, respectively) and the bb genotype and the BB+Bb genotype (p = 0.004), and the carriers of the GА genotype of MCP-1 gene had a statistically significantly lower increase in the BMD of the entire proximal femur than those of the homozygous AA genotype (0.2±2.5% and 4.4±4.4%, respectively; p = 0.004) at 12 months after SR treatment.

Conclusion. The findings may suggest that the BB and Bb genotypes of the VDR gene and the GA genotype of the MCP-1 gene may negatively affect the efficacy of SR in patients with OP. However, additional studies on a larger sample of patients, including those with other forms of OP, are required to confirm this assumption. 

1. Reginster JY, Deroisy R, Jupsin I. Strontium renelate: a new paradigm in the treatment of osteoporosis. Drugs Tody (Barc). 2003 Feb;39(2):89-101. doi: 10.1358/dot.2003.39.2.799416

2. Eisman JA. Genetics of osteoporosis. Endocr Rev. 1999;20:788- 804. doi: 10.1210/edrv.20.6.0384

3. Sainz J, van Tomout JM, Loro MI, et al. Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. N Engl J Med. 1997;337:77-82. doi: 10.1056/NEJM199707103370202

4. Тагиева АН, Сметник ВП, Сухих ГТ и др. Изучение роли генов рецептора витамина Д (VDR), альфа рецептора эстрогена (ERα) и альфа 1 цепи коллагена первого типа (Col1A1) в заболеваемости постменопаузальным остеопорозом. Медицинская генетика. 2005;4(2):90-5 [Tagieva AN, Smetnik VP, Sukhikh GT, et al. A study of the role of the genes of the vitamin D receptor (VDR), the alpha receptor of estrogen (ERα) and the alpha 1 chain of collagen type 1 (Col1A1) in the incidence of postmenopausal osteoporosis. Meditsinskaya Genetika. 2005;4(2):90-5 (In Russ.)].

5. Uitterlinden AG, Burger H, Huang Q, et al. Relation of alleles of the collagen type I alpha I gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl J Med. 1998;338:1016-21. doi: 10.1056/NEJM199804093381502

6. Mizunuma H, Hosoi T, Okano Y, et al. Estrogen receptor gene polymorphism and bone mineral density at the lumbar spine of pre- and postmenopausal women. Bone. 1997;21:379-83. doi: 10.1016/S8756-3282(97)00178-6

7. Крылов МЮ, Греченко АВ, Самаркина ЕЮ и др. Ассоциация минеральной плотности костной ткани с полиморфизмами гена альфа рецептора эстрогена (ERSα) при постменопаузальном остеопорозе. Научно-практическая ревматология. 2005;43(1):8-11 [Krylov MY, Grechenko AV, Samarkina EY, et al. Mineral bone density association with estrogen alpha receptor gene (ERSα) polymorphisms at postmenopausal osteoporosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2005;43(1):8-11 (In Russ.)]. doi: 10.14412/1995-4484-2005-548

8. Langdahl DL, Knudsen JY, Jensen HK, et al. A sequence variation: 713-8delC in the transforming growth factor-beta 1 has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone. 1997;(20):289-94. doi: 10.1016/S8756- 3282(96)00363-8

9. Крылов МЮ, Маслова КА, Короткова ТА и др. Полимор- физм гена трансформирующего фактора роста бета 1 при по- стменопаузальном остеопорозе. Научно-практическая рев- матология. 2009;43(1):18-23 [Krylov MY, Maslova KA, Korotkova TA, et al. Transforming growth factor α1 gene polymorphism in postmenopausal osteoporosis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(1):18-23 (In Russ.)]. doi: 10.14412/1995-4484- 2009-137

10. Conti V, Russomanno G, Corbi G, et al. A polymorphism at the translation start site of the vitamin D receptor gene is associated with the response to anti-osteoporotic therapy in postmenopausal women from southern Italy. Int J Mol Sci. 2015 Mar 10;16(3):5452-66. doi: 10.3390/ijms16035452

11. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367:284-7. doi: 10.1038/367284a0

12. Salama MK, Sabry D, Al-Ghussein MA, et al. Molecular detection of monocyte chemotactic protein-1 polymorphism in spontaneous bacterial patients. World J Gastroenterol. 2014 Sep7;20(33):11793-9. doi: 10.3748/wjg.v20.i33.11793

13. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012;44(5):491- 501. doi: 10.1038/ng.2249

14. Ralston SH, Uitterlinden AG. Genetics of osteoporosis. Endocr Rev. 2010;31(5):629-62. doi: 10.1210/er.2009-0044

15. Creatsa M, Pliatsika P, Kaparos G, et al. The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study. J Obstet Gynaecol Res. 2011 Oct;37(10):1415-22. doi: 10.1097/FPC.Ob013e328354455c

16. Palomba S, Orio F Jr, Russo T, et al. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporosis Int. 2005;16:943-52. doi: 10.1007/s00198-004-1800-5

17. Marc J, Prezelj J, Komel R, Kocijancic A. VDR genotype and response to etidronate therapy in late postmenopausal women. Osteoporosis Int. 1999;10:303-6. doi: 10.1007/s001980050231

18. Kurabayashi T, Tomita M, Matsushita H, et al. Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. Am J Obstet Gynecol. 1999 May;180(5):1115-20. doi: 10.1016/S0002-9378(99)70603-4

19. Schnabel RB. Duffy antigen receptor for chemkines (Darc) polymorphism regulated circulating concentrations of monocyte chemoatractant protein-1 and other inflammatory mediators. Blood. 2010;115(26):5289-99. doi: 10.1182/blood-2009-05-221382

20. Eraltan H, Cacina C, Kahraman OT, et al. MCP-1 and CCR2 gene variants and the risk for osteoporosis and osteopenia. Genet Test Mol Biomarkers. 2012 Apr;16(4):229-33. doi: 10.1089/gtmb.2011.0216